ClinicalTrials.gg
RecruitingNCT05674643Updated Apr 2, 2026

Gastric Assessment of Pediatric Patients Undergoing Surgery

An observational study in Fasting, Delayed Gastric Emptying and Aspiration Pneumonia, sponsored by Boston Children's Hospital. Recruiting at 1 site in United States. Open to participants aged 2 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Boston Children's Hospital · Observational

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
2 Years to 18 Years
Sex
All
01

Study summary

The goal of this pilot prospective cohort study is to examine the reproducibility of gastric volume and emptying as measured by gastric ultrasound and its correlation to a gold-standard test for gastric emptying in the perioperative period in pediatric patients. The main questions it aims to answer are:

  • What is the reliability (inter-rater variability between expert and novice assessors, and intra-rater variability) of a) the gastric antral cross-sectional area (CSA) and b) gastric volume using the Perlas US qualitative grading assessment, measured by using an ultrasound device in pediatric patients undergoing general anesthesia for elective surgery?
  • What is the correlation between ultrasound assessment of gastric emptying by the antral-CSA and gastric emptying determined by the acetaminophen absorption test (AAT), the gold standard?

The study will include two cohorts. Cohort assignment will be based on age and anesthesia induction plan. Subjects >7yrs of age and expected to get an IV induction will be assigned to Cohort #1. Subjects \<7yrs of age and not expected to get an IV induction will be assigned to Cohort #2.

  • Cohort 1 will include abdominal ultrasound for gastric assessment AND the acetaminophen absorption test which includes administering enteral acetaminophen (tylenol) with 6 oz of water and drawing of blood samples through a peripheral intravenous line.
  • Cohort 2 will include subjects for whom a peripheral intravenous line placement is not part of routine pre-operative care. Procedures for Cohort 2 will include abdominal ultrasound only in the pre-op area (no tylenol). This cohort is included to examine the reliability of measurements across age groups.
02

Conditions studied

  • Fasting
  • Delayed Gastric Emptying
  • Aspiration Pneumonia
  • Respiratory Aspiration of Gastric Content

Keywords

  • gastric ultrasound
  • pre-operative fasting
03

In context

Fasting

392 studies on the registry are indexed under Fasting; 63 are open to participants now.

This study's planned enrollment of 60 is below the median of 100 across 74 observational studies indexed under Fasting.

Browse Fasting studies →

Lead sponsor

Boston Children's Hospital is the lead sponsor of 608 studies on the registry; 147 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This study is enrolling healthy pediatric subjects ages 2 through 17 years of age who are undergoing surgery with anesthesia at Boston Children's Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Perioperative patients with 1-2
  • Ages: 2 years- less than 18 years
  • Locations: Longwood and Waltham campuses of Boston Childrens Hospital

Exclusion criteria

Exclusion Criteria:

  • History of gastrointestinal surgery
  • Gastrostomy
  • Known GI dysmotility (cohort 1 only)
  • Acetaminophen allergy (cohort 1 only)
  • Liver or renal dysfunction- pre-diagnosed or, if available, when serum biomarkers are 2 standard deviations above the highest value considered normal for age. (cohort 1 only)
  • Consumption of acetaminophen in the 4 hours prior (cohort 1 only)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1 - ultrasound and acetaminophen

    Cohort 1 will include subjects who have a peripheral intravenous line placed in the pre-op area per routine care. This cohort is on average age 7 years and older. Procedures for cohort 1 will include: (a) gastric US measurement of the antral CSA and gastric volume using the Perlas US qualitative grading assessment by an expert and a novice operator to determine the inter-rater class reliability and repeat measurements by each operator to assess the intra-rater reliability (Aim 1), and (b) serial abdominal ultrasounds for gastric assessment and the acetaminophen absorption test to determine the correlation between gastric US and a gold-standard for gastric emptying (Aim 2). The acetaminophen absorption test requires administering a single weight-based enteral dose of acetaminophen with 6 oz of water and drawing of blood samples through a peripheral intravenous line.

    Diagnostic Test: Gastric Ultrasound Baseline Scans · Diagnostic Test: Acetaminophen Absorption Test (AAT) · Diagnostic Test: Gastric Ultrasound Serial Scans

  • Cohort 2 - ultrasound only

    Cohort 2 will include subjects for whom a peripheral intravenous line placement is not part of routine pre-operative care. Average age for cohort 2 is age less than 7 years old. Procedures for Cohort 2 will include a gastric US measurement of the antral CSA and gastric volume using Perlas US qualitative grading assessment by an expert and a novice operator to determine the inter-rater class reliability and repeat measurements by each operator for the intra-rater reliability (Aim 1). This cohort is included to examine the reliability of measurements across age groups.

    Diagnostic Test: Gastric Ultrasound Baseline Scans

Interventions

  • Diagnostic testGastric Ultrasound Baseline Scans

    The patient's abdomen will be scanned using the ultrasound device by an expert scanner and novice scanner for baseline assessment of the antral CSA and gastric volume using Perlas US qualitative grading assessment.

  • Diagnostic testAcetaminophen Absorption Test (AAT)

    Prior to starting the AAT, a baseline plasma acetaminophen level (250 microliters) will be obtained from the intravenous catheter. The subject will then be given 12.5 mg/kg or max 650mg of single batch 32mg/mL acetaminophen followed by 6oz of water PO. Up to 3 additional small volume blood samples will be drawn for acetaminophen levels. These additional blood samples (250 microliters each) will be obtained to measure acetaminophen plasma levels at the following goal intervals after acetaminophen administration.T1:10-20 mins, T2:35-45 mins, T3: 60mins. At the time of each lab draw gastric ultrasound will be assessed by the expert scanner to correlate gastric ultrasound with the acetaminophen absorption test as a gold-standard of gastric emptying.

  • Diagnostic testGastric Ultrasound Serial Scans

    Cohort 1 will have multiple scans as part of assessing gastric emptying. These sequential scans after the baseline assessment will be done in line with the Acetaminophen Absorption Test timeline (T1:10-20 mins, T2:35-45 mins, T3: 60mins) and will be performed by an expert scanner only.

06

What researchers measure

Primary outcomes

  1. Inter-rater reliability

    Measured using the following quantitative and qualitative ultrasound assessments between a novice and an expert gastric ultrasound operator: * Qualitative using the previously published Perlas' US qualitative grading assessment * Grade 0- no contents visualized in supine and lateral position * Grade 1- contents visualized in the lateral decubitus position (RLD) only * Grade 2- contents visualized in the supine and RLD. * Quantitative assessment using the cross-sectional area as published by Spencer AO et al. * Measurement of the CSA: longitudinal diameter (D1), and the antero-posterior diameter (D2) in both supine and RLD. Then these will be used to calculate the cross-sectional area (CSA) = (π\*D1\*D2)/4. * Quantitative assessment using the cross-sectional area as published by Spencer AO et al. * Measurement of the CSA: longitudinal diameter (D1), and the antero-posterior diameter (D2) in both supine and RLD. Then these will be used to calculate the cross-sectional area (CSA)

    Time frame: 1 year

  2. Intra-rater reliability

    Measured using the following quantitative and qualitative ultrasound assessments between a novice and an expert gastric ultrasound operator: * Qualitative using the previously published Perlas' US qualitative grading assessment * Grade 0- no contents visualized in supine and lateral position * Grade 1- contents visualized in the lateral decubitus position (RLD) only * Grade 2- contents visualized in the supine and RLD. * Quantitative assessment using the cross-sectional area as published by Spencer AO et al. * Measurement of the CSA: longitudinal diameter (D1), and the antero-posterior diameter (D2) in both supine and RLD. Then these will be used to calculate the cross-sectional area (CSA) = (π\*D1\*D2)/4.

    Time frame: 1 year

  3. Gastric Emptying

    Outcome will be gastric emptying assessed by the change in antral CSA (measured in cm2) over time after acetaminophen administration, and this will be correlated to gastric emptying over the same period of time by the acetaminophen absorption test PK parameter, AUC60 mcg\*min/mL. As such, each patient will act as their own control. Correlation analysis will be applied to examine the performance of CSA measurements overtime using gastric ultrasound to determine gastric emptying compared to the acetaminophen absorption test as the gold standard.

    Time frame: 1 year

Secondary outcomes

  1. Post-anesthetic outcomes

    Fasting times have been correlated to post-anesthetic outcomes such as post-operative nausea/ vomiting, and discomfort, and it is known that some patients fast longer than required by their clinical team, which can result in adverse effects. Reported fasting times for all patients and confirmatory assessment by gastric US will be examined along with data pulled from the medical record about post-operative nausea/ vomiting, post-operative discomfort, satisfaction, and whether the patient met their expected post-operative trajectory or not (e.g. unplanned admission).

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Spencer AO, Walker AM, Yeung AK, Lardner DR, Yee K, Mulvey JM, Perlas A. Ultrasound assessment of gastric volume in the fasted pediatric patient undergoing upper gastrointestinal endoscopy: development of a predictive model using endoscopically suctioned volumes. Paediatr Anaesth. 2015 Mar;25(3):301-8. doi: 10.1111/pan.12581. Epub 2014 Dec 11. PubMed 25495405 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05674643
Responsible party
Walid Alrayashi (Director, Regional Analgesia Program, Boston Children's Hospital) — Principal investigator
First posted
Jan 6, 2023
Start date
Feb 1, 2023
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 2, 2026

Study contacts

Jocelyn Booth, BSN
Contact
jocelyn.booth@childrens.harvard.edu
857-218-4585
Rachel Bernier, MPH
Contact
rachel.bernier@childrens.harvard.edu
857-218-5348

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion